Switzerland: Infarct Size Does Not Affect Treatment Effect of Early Versus Late DOAC
For individuals with minor, moderate, or major stroke, the treatment effect of early versus late direct oral anticoagulant (DOAC) initiation does not differ, according to a study published online May 28 in JAMA Neurology.
Martina B. Goeldlin, M.D., Ph.D., from the University of Bern in Switzerland, and colleagues examined whether infarct size modifies the safety and efficacy of early versus late DOAC initiation in a post-hoc analysis of participants from the multinational randomized clinical Early Versus Later Anticoagulation for Stroke With Atrial Fibrillation (ELAN) trial with acute ischemic stroke, atrial fibrillation, and brain imaging available. A composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage, extracranial bleeding, systemic embolism, or vascular death within 30 days was examined as the primary outcome.
Source: Advances and More licensed by HealthDay
